anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This study compares a routine MRI scan with a new portable MRI scanner known as the "Hyperfine" using a contrast dye called Gadopiclenol, the contrast is FDA approved. If participants choose to participate in this study, they will receive two MRI scans on the same day. One on the traditional standard of care MRI scanner and the other on the new portable Hyperfine MRI. The Hyperfine MRI scanner is not FDA approved due to being a very low risk medical device. However, the device is compliant with all of the FDA requirements regarding design control regulations and risk analysis. Participants will only receive one contrast injection that will be used for both scans. The selection of which scan is given first will be randomly selected (50/50 chance). Participation in this study will last two days. The first day participants will receive both MRI scans and the second day participants will receive a phone call from the research staff to check on them.
The invention provides prebiotics and probiotic compositions that enhance the ability of organisms to resist staphylococcus aureus infections. In particular, the invention provides the use of a combination of prebiotics comprising breast milk oligosaccharides and probiotics comprising bifidobacterium longum subsp. Infantis (Bifidobacterium longum subsp. Infantis) in the manufacture of a food or pharmaceutical product for at least one of the following efficacy: improving the resistance of organisms to staphylococcus aureus infection; improving the innate immunity of organisms; and/or anti-aging. The bifidobacterium longum subspecies infantis preferably comprises a strain with a preservation number of CGMCC No. 21109.
PURPOSE:To provide a hair tonic having extremely remarkable hair tonic effect without exhibiting side effects of hormones such as female hormones, etc., by using 4-androsten-3-one-17beta-carboxylic acid having anti-androgen activity as an active component. CONSTITUTION:4-Androsten-3-one-17beta-carboxylic acid of formula is used as an active component, and is added e.g. directly to the substrate. It is applied, pref. in the form of hair lotion, hair oil, hair cream, etc. which can be directly applied to or rubbed in the skin of the head. The amount of the active component is pref. 0.001-0.1% of the whole composition. The composition may contain salicylic acid and other pharmaceutical components, or other additives. By the direct application of the hair tonic thus obtained to the skin of the head, the falling of hair is suppressed, and the restoration and growth of hair is promoted.
BACKGROUND: Osteogenesis imperfecta (OI) is a connective tissue disorder characterized by skeletal deformities, bone fragility, and spinal complications. Various studies' insights underscored the impact of scoliosis on pulmonary function, positive outcomes with spinal fusion, and improved functional abilities post-surgery. However, partial loss of correction remains inevitable.
METHODS: This study examines six surgically treated OI patients with scoliosis. Surgical intervention using a posterior approach with pedicle screws and hooks aimed to correct spinal deformities. Preoperative, postoperative, and follow-up radiological assessments were conducted, revealing significant reductions in scoliotic angles post-surgery.
RESULTS: Complications included infections and proximal junctional kyphosis requiring revision surgeries. Despite the challenges posed by poor bone quality and implant stability, no implant failures occurred in this series. Ponte osteotomies at the apex of deformity aided in corrective maneuvers.
CONCLUSION: Surgical treatment of scoliosis in patients affected by OI is challenging and may be associated with perioperative and postoperative complications. Ponte osteotomy may improve the correction and reduce necessary force at the time of correction.
This group will not have any interaction with the Recovery Navigator. They will then have a 3 month and 6 month follow up visit. There is no drug or treatment administered to the subject.
The rate of intraoperative fluid administration will be adjusted to achieve the target of Stroke Volume Variation ≤ 12%. A crystalloid bolus of 200 ml will be repeatedly administered every 20 min until the target was achieved. The basal rate of fluid administration will be 3 ml/kg/hr.
Participants who were receiving episodic treatment with bypassing agents prior to study entry and were randomized to study Arm B continued with their prior episodic treatment regimen for the first 24 weeks of the study; they did not receive emicizumab prophylaxis during that time. After completing at least 24 weeks on study, participants in Arm B were allowed to switch to emicizumab prophylaxis (as described for Arm A) up to the end of study. Participants continued to receive bypassing agent therapy to treat any breakthrough bleeds.
"All patients will get the total intravenous anesthesia with propofol-remifentanil via an effective site-controlled infusion (TCI). For this, TCI continuous infusion pump will be used with Schnider pharmacokinetic model for propofol and Minto pharmacokinetic model for remifentanil. Propofol and remifentanil will be initiated with target effective site concentrations of 3 μg.ml-1 and 3 ng.ml-1, respectively, and controll these concentrations considering patient's consciousness loss and vital signs. And then 0.6 mg kg-1 rocuronium for muscle relaxation will be administered for intubation. Anesthesia will be maintained with BIS level 40-60 and vital signs will not be more than 20% of the baseline or less. In order to prevent the sudden movement of the patient during surgery, rocuronium will be infused continuously about 50% of TOF until the end of intraoperative neuromonitoring.
PURPOSE:To obtain human IgA secretory cell in a high yield, by cultivating human B lymphocyte in a specific human lactoferin-containing medium. CONSTITUTION:A solution obtained by dissolving or dialyzing human lactoferin against a buffer solution (e.g. imidazole buffer solution) containing 2-40mM Mg at pH about 5-9 is reacted with a nuclease (e.g. D NaseI) at 5-65 deg.C for 10-20min. Then human B lymphocyte is inoculated to a medium (e.g. medium RPMI 1640) containing 5-50mug/ml of the human lactoferin, cultivated about 30 deg.C for 3-4 days and the human B lymphocyte is differentiated and introduced to IgA secretory cell.
ACE1831 dose escalation, in combination with obinutuzumab. Lymphodepleting regimen followed by escalating doses of ACE1831, given in combination with obinutuzumab.
Verapamil hydrochloride extended-release tablets, USP is a calcium ion influx inhibitor (slow-channel blocker or calcium ion antagonist). Verapamil hydrochloride extended-release tablets, USP is available for oral administration as light blue, oval shaped, scored, film coated tablets containing 240 mg of verapamil hydrochloride USP; as light blue, capsule shaped, bevelled edged, scored, film coated tablets containing 180 mg of verapamil hydrochloride USP. The tablets are designed for sustained release of the drug in the gastrointestinal tract; sustained-release characteristics are not altered when the tablet is divided in half.

The structural formula of verapamil HCl USP is:

Verapamil HCl, USP is an almost white, crystalline powder, practically free of odor, with a bitter taste. It is soluble in water, chloroform, and methanol. Verapamil HCl, USP is not chemically related to other cardioactive drugs.

Inactive ingredients include colloidal silicon dioxide, hypromellose, magnesium stearate, microcrystalline cellulose, polyethylene glycol, polyvinylpyrrolidone, sodium alginate, and film coating contains FD&C Blue No. 1 Brilliant Blue FCF aluminum lake, hypromellose, iron oxide yellow, titanium dioxide and triacetin.

Verapamil hydrochloride extended-release tablets USP, 180 mg and 240 mg meet USP Dissolution Test 3.
An injectable formulation of a sedative hypnotic drug, such as the anesthetic drug etomidate, that is pharmaceutically stable, demonstrates a reduced incidence of pain upon injection, and is bioequivalent with currently approved formulations. The formulation of the present invention employs a sulfoalkyl ether cyclodextrin solubilizing and complexing excipient, such as CAPTISOL® cyclodextrin (sulfobutyl ether β-cyclodextrin) to form a true aqueous solution. This formulation minimizes the allergic response and microbial contamination issues typically associated with parenteral emulsion formulations. The present formulation also reduces pain on injection as compared to the known organic solvent based formulations containing etomidate. The liquid formulation can be sterile filtered unlike emulsion-type formulations of sedative hypnotics. The liquid formulation can be lyophilized or otherwise dried to yield a solid formulation.
Dinitrohalogenated compounds may be utilized by injection in certain clinical situations to provide a possibility of long term control of human malignancy. In some of those settings no other treatment offers such potential. Preparation methods may include acetone, olive oil, microsomes, liposomes, or combinations thereof. Optimum pretreatment management, dosing and injection techniques are described. 
     The unique aspects of the claims included herein include the methods of preparation of the chemical, the technique of injection, the dosage of each injection, and the range of potential tumor histologies. These techniques have resulted for example in successful treatment of locally metastatic scalp melanoma, the treatment for which had previously been uniformly unsuccessful. This example is particularly significant since this is one example of a site that is not otherwise amenable to successful treatment when affected by multiple progressive metastatic nodules. This condition was untreatable for cure by any other previous method, including surgery.
Surgery is the mainstay of treatment modality for malignant melanoma. However, the deteriorative hypoxic microenvironment after surgery is recognized as a stemming cause for tumor recurrence/metastasis and delayed wound healing. Here we design and construct a sprayable therapeutic hydrogel (HIL@Z/P/H) encapsulating tumor-targeted nanodrug and photosynthetic cyanobacteria (PCC 7942) to prevent tumor recurrence/metastasis while promote wound healing. In a postsurgical B16F10 melanoma model in female mice, the nanodrug can disrupt cellular redox homeostasis via the photodynamic therapy-induced cascade reactions within tumor cells. Besides, the photosynthetically generated O2 by PCC 7942 can not only potentiate the oxidative stress-triggered cell death to prevent local recurrence of residual tumor cells, but also block the signaling pathway of hypoxia-inducible factor 1α to inhibit their distant metastasis. Furthermore, the long-lasting O2 supply and PCC 7942-secreted extracellular vesicles can jointly promote angiogenesis and accelerate the wound healing process. Taken together, the developed HIL@Z/P/H capable of preventing tumor recurrence/metastasis while promoting wound healing shows great application potential for postsurgical cancer therapy.
The invention discloses an anti-tumor compound, a composition and application thereof. The antitumor compound is a conjugate obtained by connecting pyropheophorbide a and doxorubicin through a ketal bond, and is named as Ppa-TK-DOX. The composition containing Ppa-TK-DOX and the tumor stem cell differentiating agent takes hyaluronic acid modified with lipophilic fragments as a carrier, can be prepared into nanoparticles, and is applied to the preparation of antitumor drugs. Ppa-TK-DOX has simple synthesis method, good blood and tissue compatibility, and combines chemotherapy and photodynamic therapy to exert synergistic treatment effects. The composition has stronger effect of downregulating stem of tumor cells and stronger specific tumor accumulation capacity, and shows good tumor penetration capacity. The composition in nanoparticle form further improves antitumor efficacy.
Surgery, burns or surgery-free accident are leading causes of scars with altered tissue consistency, a reduced degree of motion and pain. Autologous fat grafting can dramatically improve tissue consistency and elasticity but less frequently results in the reduction of pain. Therefore, we analyzed different cell populations present within the adipose tissue to be engrafted and correlated them with the reduction of pain after surgery. Here, we identify a population of CD3 - CD4 - CD304 + cells present in grafted adipose tissue, whose abundance highly correlates with pain improvement shortly after surgery ( r2 = 0.7243****) as well as persistently over time (3 months later: r2 = 0.6277****, 1 year later: r2 = 0.5346***, and 4 years later: r2 = 0.5223***). These cells are characterized by the absence of the hematopoietic marker CD45, whereas they express CD90 and CD34, which characterize mesenchymal stem cells (MSCs); the concomitant presence of CD10 and CD73 in the plasma membrane supports a function of these cells in pain reduction. We deduce that the enrichment of this adipose tissue-derived MSC subset could enhance the therapeutic properties of adipose grafts and ameliorate localized pain syndromes.
Subjects will have blood drawn at 1900 hr for baseline hormone measurements. At 2200 hr each subject will take a single oral dose of dexamethasone at 2200 hr. At 0700 hr the following day, subjects will have a blood sample drawn for hormone measurements. After this blood sample, adrenocorticotropin (ACTH) will be administered as an iv bolus. At 30 and 60 minutes after ACTH, blood samples will be obtained for repeat hormone measurements.
Mucosal-associated invariant T (MAIT) cells play diverse roles in cancer, infectious diseases, and immunotherapy. This review explores their intricate involvement in cancer, from early detection to their dual functions in promoting inflammation and mediating anti-tumor responses. Within the solid tumor microenvironment (TME), MAIT cells can acquire an 'exhausted' state and secrete tumor-promoting cytokines. On the other hand, MAIT cells are highly cytotoxic, and there is evidence that they may have an anti-tumor immune response. The frequency of MAIT cells and their subsets has also been shown to have prognostic value in several cancer types. Recent innovative approaches, such as programming MAIT cells with chimeric antigen receptors (CARs), provide a novel and exciting approach to utilizing these cells in cell-based cancer immunotherapy. Because MAIT cells have a restricted T cell receptor (TCR) and recognize a common antigen, this also mitigates potential graft-versus-host disease (GVHD) and opens the possibility of using allogeneic MAIT cells as off-the-shelf cell therapies in cancer. Additionally, we outline the interactions of MAIT cells with the microbiome and their critical role in infectious diseases and how this may impact the tumor responses of these cells. Understanding these complex roles can lead to novel therapeutic strategies harnessing the targeting capabilities of MAIT cells.
This was a Phase 3, randomized, open-label, active-controlled study to evaluate the efficacy and safety of 150 milligrams (mg) of migalastat hydrochloride (migalastat) (equivalent to 123 mg of migalastat) once every other day (QOD) and ERT in male and female participants with Fabry disease who were receiving ERT and who have an α Gal-A mutation that is amenable to migalastat, based on the clinical trial HEK assay. This was a 2-part study. Part 1, the 18-month randomized phase, evaluated participants who received either migalastat 150 mg QOD or ERT per prescribing physicians' instructions for efficacy and safety. Part 2, the optional 12-month open-label extension (OLE) phase in which all participants received migalastat, also explored efficacy and safety. For Part 2, all participants who received ERT in Part 1 were given migalastat. Data presented in this posting include efficacy data from the 18-month randomized period and safety data from the entire study (18-month randomized period and 12-month optional OLE \[total of 30 months\]).
The present invention relates to medicine for relieving swelling and transforming stasis and a preparation method thereof. The medicine for relieving swelling and transforming stasis comprises main components of the following proportion by weight: 1000 shares of medicinal old vinegar, 2 to 10 shares of dragon blood, 0.5 to 2 shares of toad cake and 0.1 to 1 share of verdigris. The preparation method comprises the following steps: (1) selecting materials and mixing the materials; (2) preparing the medicine: soaking the toad cake into human milk (milk) which is once or twice of the toad cake for 2 to 5 days until the materials are dissolved into gruel paste, and grinding the materials until the granularity is less than 10 micrometers; grinding dragon blood resin until the granularity is less than 10 micrometers after the dragon blood resin is aired and dried; grinding the verdigris CuCO3. Cu(OH)2 into powder until the granularity is less than 10 micrometers; putting the gruel paste and the powder into medicinal old vinegar to be stirred uniformly and to be loaded into medicine bottles. The medicine for relieving swelling and transforming stasis of the present invention has obvious curative effects of fast activating blood and transforming stasis, relieving swelling and pain, discharging purulence, etc. The present invention has the advantages of easy preparation and convenient operation.
Patients receive doxorubicin hydrochloride IV, cyclophosphamide IV over 20-30 minutes, and placebo IV over 30-90 minutes on day 1. Treatment repeats every 2 or 3 weeks for 4 courses. Beginning 3 weeks later, patients then receive paclitaxel IV over 1 hour on days 1, 8, and 15 and placebo IV over 30-90 minutes on day 1. Treatment with paclitaxel and placebo repeats every 3 weeks for 4 courses.
Participants will perform their training at \~70% of their 1-repetition maximum, as traditionally advocated in strengthening literature. Each of the diagnoses (RA, OA, myositis) will have a High-Intensity arm.
Sepsis is a major health concern globally, and identification of the causative organism usually takes several days. Furthermore, molecular amplification using whole blood from patients with sepsis remains challenging because of primer cross-reactivity with human DNA, which can delay appropriate clinical intervention. To address these concerns, we designed primers that could reduce cross-reactivity. By evaluating these primers against human DNA, we confirmed that the cross-reactivity observed with conventional primers was notably absent. In silico PCR further demonstrated the specificity and efficiency of the designed primers across 23 bacterial species that are often associated with sepsis. When tested using blood samples from sepsis patients, the designed primers showed moderate sensitivity and high specificity. Surprisingly, our method identified bacteria even in samples that were detected at other sites but tested negative using conventional blood culture methods. Although we identified some challenges, such as contamination with Acetobacter aceti due to the saponin pretreatment of samples, the developed method demonstrates remarkable potential for rapid identification of the causative organisms of sepsis and provides a new avenue for diagnosis in clinical practice.
PURPOSE:To prepare a composition containing a fat-soluble drug, having excellent dispersibility in water, and free from the undesirable effect to the sealing surface when filled in a capsule, by compounding a fat-soluble drug with specific amounts of two kinds of polyglycerol fatty acid esters having different HLB values at a specific ratio. CONSTITUTION:A polyglycerol fatty acid ester having an HLB of >=11.5 is mixed with a polyglycerol fatty acid ester having an HLB of <=1.5 at a weight ratio (the former/the latter) of 2/3-19. 30-3,000pts.wt. of the mixture is compounded with 100pts. of a fat-soluble drug such as fat-soluble vitamins (vitamin A, D, E, K or their derivatives), isoprenoid drug having isoprene chain in the molecule, or ubidecarenone, etc. A composition containing a fat-soluble drug and suitable especially for filling in a capsule can be prepared by this process.
The scope of the HERMES study is to investigate whether the information obtained by remote monitoring in patients with severe functional mitral regurgitation who have undergone transcatheter mitral valve edge-to-edge repair with the Mitraclip system may have the potential to guide treatment decisions at follow-up visits, and improve the quality of life. Candidates to the Mitraclip procedure on optimal medical therapy will be offered the opportunity to participate to the study by bringing home a tablet and a series of sensors and wearables to collect daily information on blood pressure, oxygen saturation, weight variation, heart rate, symptoms and compliance to therapy. These variables will be blinded, stored by the tablet and downloaded by the core institution at follow-up visits. Clinicians will be encouraged to use these data to guide their decisions, personalizing drug therapies and follow-up schedules to the individual patient's need. Patients that during the run-in phase (from enrollment to 30+-7 days) will have used the tablet for \>66% of the days will undergo the Mitraclip procedure and continue to keep the tablet for up to 12 months (active group). Patients that during the run-in phase (from enrollment to 30+-7 days) will have not used the tablet for \>66% of the days, will continue the study as a control group. Predefined clinical follow up assessments for collection of study endpoints will be at 1 month post Mitraclip, 6 months post Mitraclip and 12 months post Mitraclip. Quality of life, assessed by means of the SF36v2 questionnaire, will be assessed at enrollment, pre Mitraclip, at 1 month after Mitraclip and at 12 months after Mitraclip. A series of secondary endpoints, including 6MWT assessments and consumption of resources will be also assessed.
PROBLEM TO BE SOLVED: To obtain a W/O-type anti-suntan cosmetic free from ultraviolet absorber, having excellent ultraviolet protecting effect and high safety to the skin and giving exellent feeling to the skin. SOLUTION: This anti-suntan cosmetic contains 20-60wt.% of a volatile component (e.g. dimethylpolysiloxane), 0.1-1.5wt.% of an organic-modified clay mineral(e.g. dodecyltrimethylammonium chloride) and 0.5-20wt.% of spherical resin powder(e.g. nylon powder). The cosmetic is preferably further incorporated with 1-20wt.% of an ultraviolet scattering agent (e.g. titanium oxide). It may further be compounded with various components ordinarily used in cosmetics, pharmaceuticals, etc. The cosmetic exhibits excellent ultraviolet protecting effect without using an ultraviolet absober and is smoothly spreadable on the skin.